ResearcherFirst Affiliated Hospital of Soochow UniversityNo recent work listed
Zixiang Zhang
Matched on ORCID iD 0009-0003-8268-2067; OpenAlex author ID A5071105473. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 2, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 2 papers
Papers 7
- RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression. Co-author DOI 10.1007/s13258-022-01217-0↗
- Development and validation of a tissue-based DNA methylation risk-score model to predict the prognosis of surgically resected pancreatic cancer patients. Last author DOI 10.21037/gs-22-517↗
- Huaier increases the antitumor effect of gemcitabine on pancreatic cancer in vitro and in vivo. Co-author DOI 10.21037/tcr-20-2627↗
- Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis. Co-author DOI 10.7150/jca.48661↗
- A Panel of Three Biomarkers Identified by iTRAQ for the Early Diagnosis of Pancreatic Cancer. First author DOI 10.1002/prca.201800195↗
- Identification of potential target genes in pancreatic ductal adenocarcinoma by bioinformatics analysis. First author DOI 10.3892/ol.2018.8912↗
- B7-H3 overexpression in pancreatic cancer promotes tumor progression. Co-author DOI 10.3892/ijmm.2012.1212↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dechun Li · 5 shared papers, 2013–2022 · strength 0.54
- Paper Huaier increases the antitumor effect of gemcitabine on pancreatic cancer in vitro and in vivo. DOI 10.21037/tcr-20-2627↗
- Paper RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression. DOI 10.1007/s13258-022-01217-0↗
- Paper Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis. DOI 10.7150/jca.48661↗
- Yuchen Tang · 4 shared papers, 2018–2022 · strength 0.52
- Paper Development and validation of a tissue-based DNA methylation risk-score model to predict the prognosis of surgically re… DOI 10.21037/gs-22-517↗
- Paper RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression. DOI 10.1007/s13258-022-01217-0↗
- Paper Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis. DOI 10.7150/jca.48661↗
- Jian Zhou · 4 shared papers, 2018–2022 · strength 0.46
- Paper RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression. DOI 10.1007/s13258-022-01217-0↗
- Paper Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis. DOI 10.7150/jca.48661↗
- Paper Identification of potential target genes in pancreatic ductal adenocarcinoma by bioinformatics analysis. DOI 10.3892/ol.2018.8912↗
- Bin Yi · 3 shared papers, 2021–2022 · strength 0.42
- Paper Development and validation of a tissue-based DNA methylation risk-score model to predict the prognosis of surgically re… DOI 10.21037/gs-22-517↗
- Paper RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression. DOI 10.1007/s13258-022-01217-0↗
- Paper Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis. DOI 10.7150/jca.48661↗
- Dongming Zhu · 3 shared papers, 2019–2022 · strength 0.38
- Paper Huaier increases the antitumor effect of gemcitabine on pancreatic cancer in vitro and in vivo. DOI 10.21037/tcr-20-2627↗
- Paper RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression. DOI 10.1007/s13258-022-01217-0↗
- Paper A Panel of Three Biomarkers Identified by iTRAQ for the Early Diagnosis of Pancreatic Cancer. DOI 10.1002/prca.201800195↗
- Jun Yao · 2 shared papers, 2021–2022 · strength 0.26
- Jian Yang · 2 shared papers, 2019–2022 · strength 0.25
- Haoran Li · 1 shared paper, 2022 · strength 0.16
- Jie Wang · 1 shared paper, 2022 · strength 0.16
- Ye Li · 1 shared paper, 2022 · strength 0.16
- Xin Zhao · 1 shared paper, 2021 · strength 0.15
- Dongbao Li · 1 shared paper, 2021 · strength 0.15
- Tao Chen · 1 shared paper, 2021 · strength 0.15
- Jian Yang · 1 shared paper, 2022 · strength 0.13
- Qiuhua Liu · 1 shared paper, 2022 · strength 0.13
- Yi Zhang · 1 shared paper, 2022 · strength 0.13
- Yujie Huang · 1 shared paper, 2022 · strength 0.13
- Yijun Wei · 1 shared paper, 2021 · strength 0.13
- Xing Wu · 1 shared paper, 2019 · strength 0.10
- Xin Zhao · 1 shared paper, 2013 · strength 0.03
- Hua Zhao · 1 shared paper, 2013 · strength 0.03
- Zhi Li · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.